Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Factors influencing outcomes in therapy-related myeloid neoplasms following allogeneic hematopoietic stem cell transplantation

Noora Obaidallah, Sihath Singhabahu, Mats Remberger, Dennis Kim, Auro Viswabandya, Rajat Kumar, Fotios Michelis, Arjun Law, Igor Novitzky-Basso, Tommy Alfaro Moya, Eshrak Al-Shaibani, Jonas Mattsson, Ivan Pasic

Blood (2025) 146 (Supplement 1): 7823.

https://doi.org/10.1182/blood-2025-7823

Published: 2025

Journal Articles

Frailty as a prognostic factor in younger adult patients with Acute Myeloid Leukemia undergoing allogeneic stem cell transplantation

Sergio Rodriguez-Rodriguez, Nihar Desai, Maria Queralt Salas Gay, Eshrak Al-Shaibani, Igor Novitzky-Basso, Arjun Law, Auro Viswabandya, Fotios Michelis, Jonas Mattsson, Dennis Kim, Rajat Kumar, Tommy Alfaro Moya

Blood (2025) 146 (Supplement 1): 4430.

https://doi.org/10.1182/blood-2025-4430

Published: 2025

Journal Articles

Post-transplant monitoring of multiparameter flow-cytometry (MFC)-based measurable residual disease (MRD) assessment combined with T-cell chimerism following allogeneic stem cell transplantation (HCT) in Acute Myeloid Leukemia (AML) and myelodysplastic syndrome (MDS)

Reem Alasbali, Majed Altareb, Carol Chen, Tommy Alfaro Moya, Eshrak Al-Shaibani, Swe Linn, Ivan Pasic, Igor Novitzky-Basso, Arjun Law, Fotios Michelis, Auro Viswabandya, Rajat Kumar, Jonas Mattsson, Raja Prince-Eladnani, Anne Tierens, Dennis Kim

Blood (2025) 146 (Supplement 1): 4295.

https://doi.org/10.1182/blood-2025-4295

Published: 2025

Journal Articles

Relapse with post-transplant tyrosine kinase inhibitor (TKI) maintenance therapy in phliladelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) after allogeneic hematopoietic stem cell transplantation: Incidence and risk factor analysis

Eshrak Al-Shaibani, Jonas Mattsson, Yu Cai, Xianmin Song, Mohsen Al Zahrani, Mohamed Elemary, Hanan Alkhaldi, Muhned Alhumaid, Ayman Saad, Francesca Biavasco, Robert Zeiser, Dennis Kim

Blood (2025) 146 (Supplement 1): 4273.

https://doi.org/10.1182/blood-2025-4273

Published: 2025

Journal Articles

Comparison of alemtuzumab and ATG-based conditioning in adult recipients of allogeneic hematopoietic cell transplantation (HCT) for severe aplastic anemia: A retrospective study

Murad Almowarey, Nihar Desai, Mohammed Kawari, Eshrak Al-Shaibani, Tommy Alfaro Moya, Arjun Law, Igor Novitzky-Basso, Ivan Pasic, Fotios Michelis, Auro Viswabandya, Dennis Kim, Jonas Mattsson, Rajat Kumar

Blood (2025) 146 (Supplement 1): 4207.

https://doi.org/10.1182/blood-2025-4207

Published: 2025

Journal Articles

Multicenter Retrospective Analysis on the Clinical Benefit of Post-Transplant Tyrosine Kinase Inhibitor (TKI) Maintenance Therapy in Ph-Positive Acute Lymphoblastic Leukemia Suggests Improved GvHD-Free, Relapse Free Survival and Non-Relapse Mortality, but Not the Risk of Relapse

Eshrak Al-Shaibani, Yu Cai, Xianmin Song, Mohsen Al Zahrani, Mohamed Elemary, Muhned Alhumaid, Hanan Alkhaldi, Ayman Saad, Francesca Biavasco, Robert Zeiser, Joon Ho Moon, Sang Kyun Sohn, Jonas Mattsson, Dennis Dong Hwan Kim

Blood (2024) 144 (Supplement 1): 4930.

https://doi.org/10.1182/blood-2024-211761

Published: 2024

Journal Articles

FLAG-IDA Plus Venetoclax in High-Risk Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia: The Princess Margaret Cancer Center Experience

Eshrak Al-Shaibani, Marta Beata Davidson, Aniket Bankar, Steven M. Chan, Hassan Sibai, Dawn C. Maze, Aaron D Schimmer, Mark D. Minden, Karen Yee, Vikas Gupta, Andre C. Schuh, Guillaume Richard-Carpentier

Blood (2024) 144 (Supplement 1): 4273.

https://doi.org/10.1182/blood-2024-209476

Published: 2024

Journal Articles

Prospective Assessment of Co-Morbidities and Framingham Risk Score in Newly Diagnosed Chronic Myeloid Leukemia (CML) Patients and Its Impact on Clinical Outcomes Following Frontline TKI Therapy: Toronto CML Genomic Alliance in Greater Toronto Area & Ontario (TCGA-GTA)

May Chiu, Gopila Gupta, Maria Agustina Perusini, Eshrak Al-Shaibani, Jenny Ho, Dennis Dong Hwan Kim

Blood (2023) 142 (Supplement 1): 1810.

https://doi.org/10.1182/blood-2023-185370

Published: 2023

Journal Articles

Impact of Kidney Dysfunction on Overall Survival in Myeloproliferative Neoplasms: A Single-Center Retrospective Study

Eshrak Al-Shaibani, Taylor Young, Eshetu Atenafu, Verna Cheung, Safwan Alsibai, Vikas Gupta, Dawn C. Maze, Marta Beata Davidson, Aniket Banker, Hassan Sibai

Blood (2023) 142 (Supplement 1): 6439.

https://doi.org/10.1182/blood-2023-189318

Published: 2023

Journal Articles

Outcomes of Allogeneic HSCT in Elderly Patients (70 years old and above) -a Canadian Experience

Yomna Eissa, Eshrak Al-Shaibani, Carol Chen, Shiyi Chen, Igor Novitzky-Basso, Arjun D. Law, Wilson Lam, Fotios Michelis, Auro Viswabandya, Armin Gerbitz, Ivan Pasic, Dennis D. H. Kim, Jeffrey H. Lipton, Jonas Mattsson, Rajat Kumar

Blood (2023) 142 (Supplement 1): 3733.

https://doi.org/10.1182/blood-2023-181118

Published: 2023

Journal Articles

Remote Monitoring of Patients after Allogeneic Stem Cell Transplantation: A Mobile Phone Application to Report Symptoms, Vital Signs and Activity in Real Time

Armin Gerbitz, Eshrak Al-Shaibani, Andrew Quirke, Abir Abbas, Rajshri Jayaraman

Blood (2023) 142 (Supplement 1): 7193.

https://doi.org/10.1182/blood-2023-178270

Published: 2023

Journal Articles

Retrospective Study to Evaluate Probability of MR4 Maintenance Following Frontline Nilotinib Dose De-Escalation after MR4 Achievement in the Patients with Chronic Myeloid Leukemia in Chronic Phase

Eshrak Al-Shaibani, Maria Agustina Perusini, Josephine Anne Lucero, Gopila Gupta, May Chiu, Filza Gul, Dennis D. H. Kim

Blood (2023) 142 (Supplement 1): 6386.

https://doi.org/10.1182/blood-2023-187689

Published: 2023

Journal Articles

New Pattern of Emerging Somatic Mutations in Optimal Responders Following Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia Patients Evidenced from Mutational Kinetic Analysis Based on Pairwise Comparison

Gopila Gupta, May Chiu, Eshrak Al-Shaibani, Maria Agustina Perusini, Josephine Lucero, Daniela Zackova, Ivana Jeziskova, Anezka Kvetkova, Tomas Jurcek, Jaeyoon John Kim, Danielle Pyne, Anthea Travas, Amirthagowri Ambalavanan, Jiri Mayer, Jessie Medeiros, Sagi Abelson, Dennis Dong Hwan Kim

Blood (2023) 142 (Supplement 1): 4531.

https://doi.org/10.1182/blood-2023-189827

Published: 2023

Journal Articles

Real World Experience of FLT3-Inhibitor Post-Transplant Maintenance with Sorafenib Demonstrating Superior Overall- and Relapse Free Survival Following Allogeneic Hematopoietic Stem Cell Transplantation in FLT3-ITD Mutated Acute Myeloid Leukemia

Yomna Eissa, Eshrak Al-Shaibani, Igor Novitzky-Basso, Ivan Pasic, Wilson Lam, Jose-Mario Capo-chichi, Arjun D. Law, Fotios Michelis, Auro Viswabandya, Armin Gerbitz, Rajat Kumar, Jonas Mattsson, Dennis D. H. Kim

Blood (2023) 142 (Supplement 1): 3589.

https://doi.org/10.1182/blood-2023-185951

Published: 2023

Journal Articles

Frailty Scale for Outcome Predictions in Hematopoietic Cell Transplanted Adults

Maria Queralt Salas, Eshetu G Atenafu, Eshrak Al-Shaibani, Ora Bascom, Leeann Wilson, Carol Chen, Ivan Pasic, Arjun Law, Wilson Lam, Dennis Dong Hwan Kim, Armin Gerbitz, Auro Viswabandya, Jeffrey H. Lipton, Fotios Michelis, Jonas Mattsson, Shabbir Alibhai, Rajat Kumar

Blood (2021) 138 (Supplement 1): 110.

https://doi.org/10.1182/blood-2021-153710

Published: 2021

Journal Articles

Impact of Age on Hospitalization and Readmission on Post Allogeneic Stem Cell Transplantation Outcome, Single Center Experience

Eshrak Al-Shaibani, Shiyi Chen, Wilson Lam, Arjun Law, Ivan Pasic, Fotios Michelis, Auro Viswabandya, Dennis Dong Hwan Kim, Sr., Armin Gerbitz, Jeffrey H. Lipton, Jonas Mattson, Rajat Kumar

Blood (2021) 138 (Supplement 1): 4122.

https://doi.org/10.1182/blood-2021-146275

Published: 2021

Journal Articles

Risk Factors for Primary and Secondary Graft Failure in Allogenic Hematopoietic Cell Transplantation: A Single Center Study

Zeyad Al-Shaibani, MD, Eshrak AL-Shaibani, MD, Mats Remberger, PhD, Wilson Lam, MD, Arjun Law, MD, Fotios V. Michelis, MD PhD, Auro Viswabandya, MD, Dennis Dong Hwan Kim, MD, Jeffrey H. Lipton, MD PhD, Jonas Mattson, MD PhD, Rajat Kumar, MD

Blood (2019) 134 (Supplement_1): 2046.

https://doi.org/10.1182/blood-2019-124208

Published: 2019

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Factors influencing outcomes in therapy-related myeloid neoplasms following allogeneic hematopoietic stem cell transplantation

Frailty as a prognostic factor in younger adult patients with Acute Myeloid Leukemia undergoing allogeneic stem cell transplantation

Post-transplant monitoring of multiparameter flow-cytometry (MFC)-based measurable residual disease (MRD) assessment combined with T-cell chimerism following allogeneic stem cell transplantation (HCT) in Acute Myeloid Leukemia (AML) and myelodysplastic syndrome (MDS)

Relapse with post-transplant tyrosine kinase inhibitor (TKI) maintenance therapy in phliladelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) after allogeneic hematopoietic stem cell transplantation: Incidence and risk factor analysis

Comparison of alemtuzumab and ATG-based conditioning in adult recipients of allogeneic hematopoietic cell transplantation (HCT) for severe aplastic anemia: A retrospective study

Multicenter Retrospective Analysis on the Clinical Benefit of Post-Transplant Tyrosine Kinase Inhibitor (TKI) Maintenance Therapy in Ph-Positive Acute Lymphoblastic Leukemia Suggests Improved GvHD-Free, Relapse Free Survival and Non-Relapse Mortality, but Not the Risk of Relapse

FLAG-IDA Plus Venetoclax in High-Risk Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia: The Princess Margaret Cancer Center Experience

Prospective Assessment of Co-Morbidities and Framingham Risk Score in Newly Diagnosed Chronic Myeloid Leukemia (CML) Patients and Its Impact on Clinical Outcomes Following Frontline TKI Therapy: Toronto CML Genomic Alliance in Greater Toronto Area & Ontario (TCGA-GTA)

Impact of Kidney Dysfunction on Overall Survival in Myeloproliferative Neoplasms: A Single-Center Retrospective Study

Outcomes of Allogeneic HSCT in Elderly Patients (70 years old and above) -a Canadian Experience

Remote Monitoring of Patients after Allogeneic Stem Cell Transplantation: A Mobile Phone Application to Report Symptoms, Vital Signs and Activity in Real Time

Retrospective Study to Evaluate Probability of MR4 Maintenance Following Frontline Nilotinib Dose De-Escalation after MR4 Achievement in the Patients with Chronic Myeloid Leukemia in Chronic Phase

New Pattern of Emerging Somatic Mutations in Optimal Responders Following Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia Patients Evidenced from Mutational Kinetic Analysis Based on Pairwise Comparison

Real World Experience of FLT3-Inhibitor Post-Transplant Maintenance with Sorafenib Demonstrating Superior Overall- and Relapse Free Survival Following Allogeneic Hematopoietic Stem Cell Transplantation in FLT3-ITD Mutated Acute Myeloid Leukemia

Frailty Scale for Outcome Predictions in Hematopoietic Cell Transplanted Adults

Impact of Age on Hospitalization and Readmission on Post Allogeneic Stem Cell Transplantation Outcome, Single Center Experience

Risk Factors for Primary and Secondary Graft Failure in Allogenic Hematopoietic Cell Transplantation: A Single Center Study

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only